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ABSTRACT
Crohn’s disease is characterised by recurrent and/or
chronic inﬂammation of the gastrointestinal tract leading
to cumulative intestinal tissue damage. Treatment
tailoring to try to prevent this tissue damage as well as
achieve optimal beneﬁt/risk ratio over the whole disease
course is becoming an important aspect of Crohn’s
disease management. For decades, clinical symptoms
have been the main trigger for diagnostic procedures
and treatment strategy adaptations. However, the
correlation between symptoms and intestinal lesions is
only weak. Furthermore, preliminary evidence suggests
that a state of remission beyond the simple control of
clinical symptoms, and including mucosal healing, may
be associated with better disease outcome. Therefore
monitoring the disease through the use of endoscopy
and cross-sectional imaging is proposed. However, the
degree of mucosal or bowel wall healing that needs to
be reached to improve disease outcome has not been
appropriately studied. Furthermore, owing to their
invasive nature and cost, endoscopy and cross-sectional
imaging are not optimal tools for the patients or the
payers. The use of biomarkers as surrogate markers of
intestinal and systemic inﬂammation might help. Two
biomarkers have been most broadly assessed in Crohn’s
disease: C-reactive protein and faecal calprotectin. These
markers correlate signiﬁcantly with endoscopic lesions,
with the risk of relapse and with response to therapy.
They could be used to help make decisions about
diagnostic procedures and treatment. In particular, with
the use of appropriate threshold values, they could
determine the need for endoscopic or medical imaging
procedures to conﬁrm the disease activity state.
INTRODUCTION
Crohn’s disease (CD) is a chronic inﬂammatory dis-
order of the gastrointestinal tract leading to cumu-
lative intestinal tissue damage and complications
such as ﬁstulas and strictures requiring surgical
resection.1 A classical step-up strategy in which the
treatment is adapted according to the clinical activ-
ity of the disease does not seem to be able to
change the natural history of the disease, particu-
larly to avoid the need for intestinal surgical resec-
tion.2 Achieving mucosal healing has been
associated with better patient outcome in several
population-based studies and clinical trials.3–6 For
these reasons and although there is no current
proof that optimising therapy in a patient who has
achieved clinical remission but not mucosal healing
will lead to improved outcome, there is an intuitive
trend to aim to achieve such healing, particularly in
patients with worse prognoses. Because of the poor
correlation between clinical activity of CD and
mucosal healing,7 this requires speciﬁc monitoring,
deﬁned as the systematic use of objective tools able
to assess the state of biological activity of the
disease, beyond the simple assessment of clinical
symptoms. Endoscopy is an invasive and costly pro-
cedure, and regular monitoring of the disease by
endoscopy may not be realistic. Moreover, it is not
adapted for small-bowel location above the ter-
minal ileum, and it does not provide information
about the transmural nature of the inﬂammation.
For these locations and aspects, cross-sectional
imaging may be more appropriate, but the speciﬁc
features associated with tissue healing have been
less well described.8 Biomarkers may represent an
attractive alternative for both colonic and small-
bowel disease, as they represent potential surrogate
markers of intestinal inﬂammation and tissue
lesions. Among the very large number of biomar-
kers assessed in CD, the vast majority have not
been adequately studied to determine their poten-
tial clinical usefulness. For most of these markers,
abnormal stool or blood concentrations have been
shown in CD, but no correlation has been clearly
demonstrated with disease activity, intestinal lesions
or disease evolution and risk of complications. The
main exceptions are blood C-reactive protein
(CRP) and faecal calprotectin, which have been
more extensively studied, including assessment of
their ability to predict response to treatment,
mucosal healing, and risk of relapse and of compli-
cations.9 Depending on the clinical situation, differ-
ent combinations of these imaging and biomarker
monitoring tools may be used. The aim of this
review is to describe the potential use, advantages
and limitations of endoscopy, cross-sectional
imaging and biomarkers for the monitoring of CD.
We will more speciﬁcally tackle these issues
through various clinical scenarios, including con-
ﬁrmation of disease activity, response to induction
therapy, conﬁrmation of sustained mucosal healing,
and prevention of relapse or recurrence. We will
not address the use of these tools for the diagnosis
of CD or when the clinical presentation leads to
the suspicion of a complication of the disease.
ENDOSCOPY
Preliminary mainly retrospective data or post hoc
analyses indicate that achieving endoscopic mucosal
healing may improve outcome of the disease.3–6
However, endoscopy suffers from a series of signiﬁ-
cant drawbacks: it is not that well accepted by the
patients,10 although it is usually safe,11 it is rela-
tively expensive, it does not give information on
the deep layers of the intestine and the extraintest-
inal signs of inﬂammation,12 and ﬁnally the
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signiﬁcance of different types of lesion and the degree of endo-
scopic healing that should be achieved is not well established.
Illustrations of unhealed, partly healed and fully healed mucosa
are shown in ﬁgure 1. Advantages and drawbacks of endoscopy
as a monitoring tool are summarised in table 1. The potential
role of endoscopy in monitoring patients with clinically active
disease or in remission is developed in the following paragraphs
and summarised in tables 4 and 5.
Conﬁrming disease activity and severity of lesions
The correlation between clinical activity of CD and the severity
of endoscopic lesions is only weak.7 Of patients with clinically
active disease, a signiﬁcant proportion will have no signiﬁcant
endoscopic lesions. These patients do not respond optimally to
the most effective treatment of CD, such as immunosuppressant
and anti-tumour necrosis factor (TNF) combination therapy.13
Preliminary data also indicate that deep colonic ulcers covering
more than 10% of a colonic segment are associated with
increased risk of colectomy over the next 8 years.14 Stricturing
lesions have been associated with lower response rate to medical
therapies and a greater need for surgery.15 To be fully
informative, an endoscopic procedure for CD should thus lead
to a very precise description of the type, location and extent of
the lesions. Although endoscopic indexes of disease severity
such as the CD Endoscopic Index of Severity (CDEIS)16 and
Simpliﬁed Endoscopic Score of CD (SESCD)17 have been used
in several studies, and speciﬁc thresholds of these scores have
been associated with CD outcome, these thresholds have not
been broadly validated. Hence, therapeutic decisions still seem
to be best based on the precise description of the lesions,
instead of a speciﬁc quantitative or semiquantitative threshold.
Conﬁrming mucosal healing
Achieving endoscopic healing after medical therapy has been
associated with a better disease outcome. In a population-based
study from Norway, the presence of mucosal healing 1 year after
the diagnosis of CD tended to be associated with less need for
surgical resection, although this difference did not reach statis-
tical signiﬁcance.3 In the Accent 1 trial, patients achieving
mucosal healing at weeks 12 and 54 experienced fewer relapses
and hospitalisations.18 In the experience of a tertiary referral
centre in Belgium, patients achieving at least partial healing
Figure 1 Examples of various degrees of endoscopic healing in Crohn’s disease. (A) Absence of healing characterised by the persistence of a deep
ulcer in the caecum; (B) absence of healing characterised by the persistence of extensive longitudinal and transversal ulcers in the sigmoid colon;
(C) absence of healing characterised by the persistence of multiple deep ulcers in the left colon; (D) partial healing characterised by the presence of
small pseudo-polyps and the persistence of focal erythema and tiny superﬁcial ulcers in the right colon; (E) partial healing characterised by the
presence of small pseudo-polyps, healed ulcers with modiﬁcation of the vascular pattern, and the persistence of small superﬁcial ulcers in the
sigmoid colon; (F) partial healing characterised by the persistence of tiny aphthous lesions throughout the colon; (G) full mucosal healing
characterised by the presence of longitudinal healed whitish areas; (H) full mucosal healing characterised by the presence of whitish healed areas
and mucosal bridges; (I) full mucosal healing characterised by the presence of mucosal bridges converging to a healed stellar-shaped area.
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subsequently underwent fewer surgical resections.4 Very interest-
ingly and intriguingly, the patients with partial healing had no
more surgery than those with complete healing, emphasising the
relevance of the question about the degree of healing required
to improve disease outcome in CD. The long-term follow-up of
the so-called ‘step-up top-down trial’ also revealed that patients
with complete mucosal healing 2 years after the beginning of
the trial (whatever the type of treatment they received) experi-
enced fewer ﬂares and were more often in remission without
steroids and without anti-TNF over the next 2 years.19 In a con-
trolled trial showing the superiority of adalimumab maintenance
over placebo to achieve early and sustained mucosal healing in
CD, the patients with mucosal healing after 12 weeks had fewer
relapses and hospitalisations over the 1-year follow-up.6 On the
basis of these preliminary data, endoscopic monitoring after
induction or during maintenance therapy is now advocated by
many experts. However, there are currently no data to clarify
the timing of this monitoring, the degree of healing that needs
to be reached, and, above all, the management of insufﬁciently
healed patients. No prospective or even retrospective study can
report on an improved outcome in these unhealed patients after
a change in therapy. This is even more troubling because the
only available data in this ﬁeld, dating back to the time of cor-
ticosteroid therapy, do not support such treatment optimisation.
Indeed, in the 1990s, a GETAID Study showed that prolonging
steroid treatment in patients in clinical remission but with
unhealed mucosa after 6 weeks of full steroid induction did not
improve the relapse rate over 1 year, despite a slight increase in
the proportion of patients whose mucosa was healed.20 Because
of all these unsettled issues, the use of endoscopic monitoring
to conﬁrm tissue healing in CD can only be empirical. An
endoscopy should only be discussed if a clear disease manage-
ment plan can be proposed to the patient depending on the
results of this endoscopy. In our view, this could be particularly
adapted when there is concern about disease progression and its
consequences. In some situations, such as extensive small-bowel
disease, previous multiple intestinal resections, deep and exten-
sive colonic (particularly sigmoid or rectal) ulcers, due to the
consequences of uncontrolled disease, endoscopic monitoring
and treatment optimisation in the case of persisting signiﬁcant
lesions may be proposed.
Assessing the patient before therapy de-escalation
In order to achieve optimal beneﬁt/cost and beneﬁt/risk ratio for
the patient, treatment de-escalation in patients who have
reached sustained remission may be as important as treatment
optimisation in those who have not reached this target.
Whether treatment de-escalation is possible in a subset of
patients and what the criteria should be is not precisely known.
However, preliminary results are provided by a prospective
cohort study from the GETAID. In this study, full endoscopic
healing was associated with a lower risk of relapse after inﬂixi-
mab withdrawal in patients treated with immunosuppressant/
inﬂiximab combination therapy for more than 1 year and in
steroid-free remission for more than 6 months.21 In patients
without mucosal healing, deﬁned by a CDEIS >0, the relapse
rate over 1 year was above 60%. Therefore endoscopic explor-
ation could be advocated in these patients before a decision is
made on such drug withdrawal. However, mucosal healing is
not the best individual predictor, and the prediction is signiﬁ-
cantly improved if some demographic characteristics, blood tests
and faecal calprotectin are integrated.
Predicting postoperative recurrence
The postoperative setting is a situation where the use of endo-
scopic monitoring has been particularly widely used in routine
practice. The disease is usually clinically quiescent, but the
recurrence rate is known to be very high. This recurrence has
been well described in the seminal paper by Rutgeerts et al.22
Over 8 years after an ileocolonic resection, ∼90% experienced
endoscopic recurrence, 60% clinical recurrence and 30% surgi-
cal recurrence. This study also showed that the clinical recur-
rence rate was strongly associated with endoscopic recurrence
within 1 year of ileocolonic resection. Diffuse ileitis, strictures
and large or deep ulcers (Rutgeerts scores i3 and i4) were asso-
ciated with almost 90% of clinical relapse over 8 years, while
no lesion or a few aphthoid ulcers (Rutgeerts scores i0 and i1)
were associated with a clinical relapse rate of ∼10%. Following
these results, it has become common practice to perform
Table 2 Monitoring of CD with cross-sectional imaging
Advantages Drawbacks
▸ Visualisation of the small bowel
▸ Assessment of the transmural and extramural inflammatory process
▸ Possibility of visualisation of the small bowel and the colon in one procedure with MRI
enterocolonography
▸ Validated score of activity for terminal ileum and the colon with MRI enterocolonography
▸ Moderate acceptance of enterography and colonography using
enema
▸ Relatively high cost of MRI and CT
▸ Only partial visualisation of the small bowel with US
▸ Ionising radiation with CT
▸ No validated score of activity with US and CT
▸ Timing of the monitoring with cross-sectional imaging not
established
▸ Degree of healing required to affect disease outcome not
established
CD, Crohn’s disease; US, ultrasonography.
Table 1 Monitoring of Crohn’s disease with ileocolonoscopy
Advantages Drawbacks
▸ Direct visualisation of
intestinal lesions
▸ Validated index of severity
▸ Predictive value for
– Postoperative recurrence
– Risk of relapse upon
anti-TNF withdrawal
– Risk of requiring abdominal
surgery under anti-TNF
therapy




▸ Relatively high cost
▸ No visualisation of the transmural
inflammatory process
▸ Timing of the endoscopic monitoring
not established
▸ Degree of healing to achieve in order
to affect disease outcome not
established
TNF, tumour necrosis factor.
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ileocolonoscopic surveillance once, between 6–12 months
after ileocolonic resection in order to adapt treatment according
to the results.
Potential role for small-bowel capsule endoscopy
Small-bowel capsule endoscopy may have much better accept-
ance than classical endoscopic explorations. It can also visualise
the whole small bowel, and its diagnostic yield in small-bowel
lesions of CD has been well established.23 It could thus be of
help in assessing disease activity or mucosal healing in the small
bowel. However, it is hampered by a relatively high retention
rate in CD, above 10%.23 Although this can usually be avoided
by a test with a patency capsule, obstructive accidents may still
occur. Furthermore, for this disease location, it is in competition
with cross-sectional imaging techniques (see below), which may
also offer information on transmural inﬂammation and assess
stricturing and ﬁstulising complications.8 Some lesions missed at
cross-sectional imaging may be diagnosed by capsule endoscopy,
particularly in the proximal small bowel, but their clinical
signiﬁcance is still unclear.24 Several small-bowel capsule endos-
copy indexes of severity have been proposed but not yet
broadly validated.23
Small-bowel capsule endoscopy has been speciﬁcally assessed
in the postoperative recurrence setting. Its correlation with ileo-
colonoscopy appears to be good, and it may thus represent an
alternative in this situation.23
CROSS-SECTIONAL IMAGING TECHNIQUES
FOR THE MONITORING OF CD
Although it may currently be considered the gold standard, the
monitoring of CD activity and mucosal healing by ileocolono-
scopy or small-bowel capsule endoscopy is hampered by a series
of drawbacks highlighted above. Therefore the use of cross-
sectional imaging techniques to monitor the disease is rapidly
increasing.8 These techniques, including ultrasonography (US),
CT and MRI, show both parietal and extraparietal changes
caused by the disease, and allow evaluation of small-intestinal
regions inaccessible to ileocolonoscopy, enabling the identiﬁca-
tion of a whole spectrum of lesions with good resolution.8
MRI is considered the standard imaging technique for assess-
ment in patients with CD who require many follow-up examina-
tions and are usually a young population.25 The absence of
ionising radiation, along with very high soft-tissue contrast, mul-
tiplanar images, low incidence of adverse events related to the
intravenous contrast, and high diagnostic accuracy in the evalu-
ation of luminal and extraluminal abnormalities, justify its appli-
cation.26 CT has a similar accuracy to MRI for assessing bowel
damage in CD,27 but the risk of radiation exposure should limit
its use as a monitoring tool. US is another non-ionising alterna-
tive,28 but has some drawbacks such as the difﬁculty of visualis-
ing deep bowel segments, high interobserver variability, and
often incomplete exploration due to gas interposition.29
An illustration of monitoring of multifocal small-bowel CD
with MR enterography is shown in ﬁgure 2. Advantages and
drawbacks of cross-sectional imaging as a monitoring tool are
summarised in table 2. The potential role of cross-sectional
imaging in monitoring patients with clinically active disease or
in remission is developed in the following paragraphs and sum-
marised in tables 4 and 5.
Assessment of disease activity and severity and response
to treatment
The high accuracy of MR enteroclysis, enterography and entero-
colonography has been demonstrated in the assessment of activ-
ity and severity in CD, with several parameters related to the
degree of activity being identiﬁed.30 Globally, enterography has
been preferred to enteroclysis because of its better acceptance.
Enterocolonography implies a colonic distension by enema and
may provide information on the whole gastrointestinal tract in
only one procedure. The main MRI ﬁndings that correlate with
intestinal inﬂammation and disease activity and severity include
wall thickening, bowel wall enhancement, mural oedema (signal
hyperintensity on T2-weighted sequences) and presence of
ulcers. It is in the terminal ileum and the colon that the ability
Table 4 Potential monitoring of a patient with clinically active CD
Question Monitoring tool Prediction




Predicts CDEIS ≤6 with a sensitivity of 83% and specificity of 71%57
Predicts active endoscopic ileocolonic lesions with a sensitivity of 87% and a
specificity of 89%30 31
Is the patient going to respond to anti-TNF
therapy (before induction)?
CRP >5 mg/l
Presence of any ulcer at
ileocolonoscopy
76% response rate after first anti-TNF (compared with 46% when normal CRP)54
61% steroid-free remission with azathioprine+infliximab combination therapy
(compared with 40% without endoscopic lesion)13
Is the patient going to respond to anti-TNF
therapy (after induction)?
Faecal calprotectin decrease
Absence of sustained CRP
normalisation
Increased proportion of endoscopic healing58
Increased risk of anti-TNF loss of response59
CD, Crohn’s disease; CDEIS, CD Endoscopic Index of Severity; CRP, C-reactive protein; MaRIA, Magnetic Resonance Index of Activity; TNF, tumour necrosis factor.
Table 3 Monitoring of Crohn’s disease with blood C-reactive




▸ Relatively low cost
▸ Can be repeated as a
longitudinal monitoring tool
▸ May be combined to
improve prediction
▸ Predictive value for
– Disease relapse under or
after medical therapy
– Response to anti-TNF
treatment
– Mucosal healing
▸ Subject to non-specific variations
▸ Stool marker not always well accepted
by patients (faecal calprotectin)
▸ The correlation with mucosal healing
and transmural healing is imperfect
▸ Predictive threshold values not fully
established
TNF, tumour necrosis factor.
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Figure 2 Example of monitoring of small-bowel Crohn’s disease (CD) with MR enterography. This patient had been operated on three times for
recurring stricturing and occlusive CD in December 1998, March 2002 and December 2005. He had been continuously treated with azathioprine
between the second and third operations. He was prescribed methotrexate 15 mg/week subcutaneously immediately after the third operation. Six
months later, in June 2006, he was in clinical remission and had a normal C-reactive protein (CRP) concentration. Because of the multifocal
small-bowel CD, it was decided to monitor him with MR enterography instead of colonoscopy. The MR enterography performed in June 2006 showed
thickening of the bowel wall without strong contrast enhancement at the ileocolonic anastomosis (B) and mild thickening and wall enhancement in a
jejunal segment (A). In January 2007, the patient was still in clinical remission with a normal CRP concentration, but had mild iron-deﬁciency anaemia
(haemoglobin concentration 11.7 mg/dl). The MR enterography performed at that stage showed a stable lesion at the ileocolonic anastomosis (D) and
marked contrast enhancement and thickening of the wall in the jejunal segment, together with hyperaemia of the vasa recta (comb sign) (C). The
patient was then treated with inﬂiximab in combination with methotrexate. In September 2007, the patient was still in clinical remission with normal
CRP concentration. The anaemia had disappeared. The MR enterography showed a signiﬁcant decrease in wall thickening and contrast enhancement of
the jejunal segment, but a partial small-bowel obstruction due to jejunal disease (E), while the anastomotic stricture remained unchanged (F).
Maintenance treatment combining methotrexate 15 mg/week orally and inﬂiximab 5 mg/kg every 8 weeks was prescribed .
Table 5 Potential monitoring of patients with CD in clinical remission
Question Monitoring tool Prediction (95% CI)
Has mucosal healing been
achieved?
CRP ≤10 mg/l and faecal calprotectin
≤200 μg/g
CDEIS ≤3 with a sensitivity of 78% and specificity of 58%57
What is the risk of relapse? Increased CRP
Increased faecal calprotectin
Mucosal healing at ileocolonoscopy
(SESCD=0)
Relative risk of relapse increasing to 3–58*70–72
Clinical relapse over 1 year with a sensitivity of 43–90% and a specificity of
43–88% (depending on the threshold for faecal calprotectin)*67–69
69% of remission without steroids over the next 2 years (compared with 38% if no
mucosal healing)19
What is the risk of abdominal
surgery?
Mucosal healing at ileocolonoscopy (at least
partial)
14% requiring abdominal surgery (vs 38% if absence of healing)4
What is the risk of relapse upon
anti-TNF withdrawal?
CRP ≥5 mg/l
Faecal calprotectin ≥300 μg/g
Absence of mucosal healing at
ileocolonoscopy (CDEIS >0)
HR for relapse 2.5 (1.4–4.4)21
HR for relapse 3.2 (1.7–6.2)21
HR for relapse 1.8 (1.0–3.3)21
What is the risk of postoperative
clinical recurrence?
Endoscopic Rutgeerts score within
6–12 months after surgical resection
i0–i1: 10% of relapse at 8 years22
i2: 40% of relapse at 8 years22
i3–i4: 90% of relapse at 8 years22
*Increase in CRP and faecal calprotectin occurs within the 4–6 months before relapse.73
CD, Crohn’s disease; CDEIS, CD Endoscopic Index of Severity; CRP, C-reactive protein; SESCD, Simplified Endoscopic Score of CD; TNF, tumour necrosis factor.
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of MRI to assess disease activity has been best validated. Using
the above parameters, Rimola et al30 31 proposed and validated
a simpliﬁed Magnetic Resonance Index of Activity (MaRIA)
score to quantify disease activity based on MRI ﬁndings in each
ileocolonic segment, which strongly correlated with CDEIS. For
the detection of active CD in the terminal ileum and the colon,
the sensitivity of this score was 87%, speciﬁcity 89%, positive
predictive value (PPV) 98%, negative predictive value (NPV)
88% and overall accuracy 98%. This score was also able to
accurately predict severely ulcerated CD. Therefore, the MaRIA
score represents an objective, quantitative and reproducible
measure of activity and could categorise disease severity and
monitor response to therapeutic interventions in the terminal
ileum and the colon.
These results agree with those from other studies identifying
MRI signs associated with pathological inﬂammation mainly in
the small bowel, using surgical examination as a reference
method.32 33 In a systematic review, Panes et al8 reported a sensi-
tivity and speciﬁcity of MRI for the assessment of disease activity
on a per patient basis of 80% and 82%, respectively. The use of
oral and intravenous contrast agent promotes bowel lumen dis-
tension and improves detection of these features.34 CT has a
similar accuracy to MRI for distinguishing activity in the terminal
ileum, with a sensitivity of 81% and speciﬁcity of 88%.8 35 36
US has been established as a reliable imaging technique for
the assessment of disease activity in CD. The wall thickness and
vascularisation pattern shown by Doppler US are particularly
useful for the detection of active disease. The overall sensitivity
and speciﬁcity of US for detecting disease activity have been
found to be ∼85% and ∼91%, respectively,8 although its per-
formance is largely dependent on the operator and the disease
location.37 The use of contrast-enhanced US seems to increase
its accuracy for the evaluation of activity in CD, with a sensitiv-
ity of 93% and speciﬁcity of 94%.38 It also seems to better clas-
sify disease severity than Doppler US signal and measurement of
wall thickening.
Few studies have investigated the capability of MRI for asses-
sing treatment response after a ﬂare of CD. Sempere et al39
evaluated this capability of MRI compared with ileocolonoscopy
in patients in the active phase of disease or in remission and in
healthy controls. These authors reported that contrast enhance-
ment of the bowel wall decreased signiﬁcantly from the active
to the remission phase. The mean contrast enhancement in
active CD was signiﬁcantly greater than in the control group,
although there was no difference between patients in remission
and the healthy controls. The same occurred with bowel wall
thickness, which was signiﬁcantly decreased in the remission
phase. However, the segments remained thickened in patients
with CD compared with healthy controls. This is probably due
to a double component: an acute factor (inﬂammation and
oedema) and a chronic factor (ﬁbrosis), which may not reverse
despite therapeutic response. Another study has evaluated MRI
for monitoring therapeutic responses using the MaRIA score
and ileocolonoscopy as a reference standard. In this setting, the
MaRIA score predicted endoscopic remission with a sensitivity
of 82% and speciﬁcity of 85%.40
All these data suggest that cross-sectional imaging could be
used for the assessment of disease activity and response to
therapy in CD. The use of a CT scanner should be avoided in
this setting to minimise irradiation. MRI enterography could
be used essentially to visualise small-bowel CD not evaluable by
standard endoscopic procedures. MRI enterocolonography,
could be used as a single exploration of the whole gastrointes-
tinal tract, particularly in ileocolonic disease, decreasing the
need for supplementary colonoscopies. This would be of par-
ticular interest for patients with both small-bowel and colonic
lesions. US is an attractive alternative, particularly in attempts
to conﬁrm active disease. However, it is less powerful than MRI
for broadly assessing lesion extent and severity, because of its
poorer performance in the colon and inability to systematically
see all intestinal segments.
Detection of complications
Chronic intestinal inﬂammation in CD can result in complica-
tions during the course of the disease. Although they may
present as acute modiﬁcations of the clinical situation leading to
emergency work up, they can also develop more silently, and
their identiﬁcation through disease monitoring may reveal
disease aggressiveness and inﬂuence treatment strategy. The
ability of cross-sectional imaging methods to demonstrate extra-
mural changes makes them accurate procedures for detecting
complications.
US, CT and MRI have a high sensitivity and speciﬁcity for the
diagnosis of stenosis affecting the large or small bowel8 identi-
ﬁed as an intestinal loop with wall thickening, narrowed lumen
and prestenotic dilation. A systematic review of pooled results
from seven studies reported that MRI had a sensitivity for
detection of stenosis of ∼89% and a speciﬁcity of ∼94%.8 This
is usually considered to be slightly higher than with CT or US.
Distinguishing between inﬂammatory and ﬁbrotic strictures is
important, as it may have a signiﬁcant effect on response to
medical treatments. Making an exclusive distinction between an
Figure 3 Example of monitoring a patient with Crohn’s disease (CD)
in clinical remission by using blood C-reactive protein (CRP) and faecal
calprotectin. This patient had been treated with azathioprine/inﬂiximab
combination therapy since July 2003 for ileocolonic refractory CD. In
March 2006, he had been in stable steroid-free remission for more than
1 year. Following a request from the patient, it was decided to
withdraw inﬂiximab and to continue with azathioprine monotherapy.
The last inﬂiximab (Ifx) infusion was administered on 15 March 2006.
At that time, CRP was slightly increased at 7.9 mg/l, but faecal
calprotectin was low at 54 μg/g. CRP and faecal calprotectin were
measured every 2 months after the last inﬂiximab infusion. While the
patient was still in remission in November 2006, a signiﬁcant increase
in faecal calprotectin was noticed (516 μg/g), whereas CRP was still
normal (3.4 mg/l). Two months later, faecal calprotectin had further
increased to 1529 μg/g, and CRP had also signiﬁcantly increased to
87 mg/l. Clinical relapse ﬁnally occurred 1 month later in February
2007.
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inﬂammatory or ﬁbrotic pattern is difﬁcult as they usually
coexist, especially in patients with severe disease.41
Nevertheless, here again, MRI may be of help. Collagen depos-
ition in the bowel wall is known to result in late gadolinium
enhancement. A decrease in the signal intensity of the thickened
wall and a reduction in bowel-wall early contrast enhancement
are usually related to intestinal ﬁbrosis.42
The diagnostic accuracy of MRI for intra-abdominal ﬁstulas
has been evaluated in multiple studies.8 Pooled results showed a
sensitivity of ∼76% and a speciﬁcity of ∼96%. CT has a similar
accuracy,43 while US is signiﬁcantly less efﬁcient.8 Likewise, MRI
detected intra-abdominal abscesses with a sensitivity ranging
from 86% to 100%, and speciﬁcity from 93% to 100%.27 With
CT, the sensitivity was 84% and speciﬁcity 97%.8 The value of
US for detection of abscesses reached a sensitivity of 81–100%
and speciﬁcity of 92–94%.8 However, US accuracy was highly
related to disease location,44 and its diagnostic accuracy was
slightly lower than that of CT and MRI because of false-positive
cases. Combining CTwith US did not signiﬁcantly improve their
diagnostic accuracy for detection of abscesses in CD.45
Assessment of postoperative disease recurrence
Although ileocolonoscopy is the gold standard technique for
evaluating recurrence of CD after intestinal resection, MRI and
US may be valuable alternatives to avoid repeated colonoscopies.
An MRI-based score has even been validated for the detection of
postoperative recurrence compared with endoscopic Rutgeerts
score.46 47 Mild bowel-wall thickening and enhancement without
stricture were considered to be signs of low-grade recurrence.
In contrast, the presence of a clear stricture and increased
bowel-wall thickness and enhancement correlated with severe
recurrence. The sensitivity and speciﬁcity of MRI for detecting
moderate to severe recurrence were 100% and 89%, respectively.
Monitoring tissue damage
Tissue damage in CD is characterised by intestinal resections,
strictures and ﬁstulising lesions.48 One of the main aims of opti-
mised therapeutic strategies for CD, including early intensive
treatment and tight disease control, is to limit, or even suppress,
the development of tissue damage. Owing to its ability to visual-
ise and quantify both stricturing and penetrating lesions of CD,
MRI currently represents the best candidate for monitoring
tissue damage in CD. A tissue damage score is currently under
development.48
BIOMARKERS
CRP is an acute phase reactant produced by the liver.49 In CD,
there is also signiﬁcant CRP production by the mesenterium
itself.50 The main trigger for CRP production is interleukin 6.51
In CD, interleukin 6 is produced in the whole intestinal wall
and probably the mesenterium, at the site of inﬂammation, by a
broad selection of cell types including lymphocytes, monocytes,
granulocytes, ﬁbroblasts, and epithelial and endothelial cells.
CRP increases very rapidly during acute inﬂammation and may
remain elevated during chronic inﬂammation.
Calprotectin is a heterodimer or heterotetramer combining
S100A8 and S100A9 proteins.52 It is produced at the site of
inﬂammation mainly by granulocytes, but also monocytes and
epithelial cells. Owing to this direct production by intestinal epi-
thelial cells, increased amounts of calprotectin may be found in
the stool even in cases of mild mucosal inﬂammation.53
Production and secretion of calprotectin is activated by sti-
mulating producing cells by inﬂammatory cytokines such
as interleukin 1, activated complement, immunoglobulins
through Fc receptor binding, and bacterial products such as
lipopolysaccharide.
Monitoring of a patient with CD in remission with blood
CRP and faecal calprotectin is illustrated in ﬁgure 3. Advantages
and drawbacks of blood CRP and faecal calprotectin as monitor-
ing tools are summarised in table 3. Their potential roles in
monitoring patients with clinically active CD or in remission is
developed in the following paragraphs and summarised in tables
4 and 5. Other blood and faecal biomarkers, such as faecal
lactoferrin, show promise as potential biomarkers for CD, but
have been studied far less extensively.9 Their place in CD moni-
toring cannot yet be discussed.
Biomarkers to conﬁrm disease activity and assess
response to treatment
The importance of conﬁrming inﬂammatory activity in a patient
with clinical symptoms before starting or escalating medical
treatment for CD has been highlighted above in the discussion
of monitoring by endoscopy and cross-sectional imaging. Blood
markers could be of help here to avoid repeating these invasive
procedures. Another feature is rapid conﬁrmation of drug efﬁ-
cacy when the treatment has been started. Here again the early
repetition of endoscopy and/or cross-sectional imaging is
inappropriate, and blood markers could provide important
information.
Conﬁrming disease activity before treatment
Although it does not correlate perfectly with endoscopic scores
of activity, CRP represents an objective marker of active inﬂam-
mation. Response to medical therapy for CD, particularly
anti-TNF antibodies, has been shown to be better when an
increase in CRP was present to conﬁrm disease activity.54 In
contrast, in patients with a normal CRP despite clinical activity
of the disease, a substantial proportion of patients may have
functional disorders or the aftermath of previous ﬂares or sur-
geries. A prospective study has speciﬁcally addressed this point
in patients with a CDAI >150 but a CRP <5 mg/l. A colonos-
copy was systematically performed; this showed only minor
lesions in the majority of the patients, but still one-third of
them had a CDEIS >6, conﬁrming clinically signiﬁcant
lesions.55 From this, it seems logical to advocate controlling
endoscopy or medical imaging for signs of disease activity in
patients with clinically active disease but a normal CRP concen-
tration. Faecal calprotectin correlates better with endoscopic
scores of disease severity, with a correlation coefﬁcient of
∼0.70.56 Although it may represent a more efﬁcient marker
than CRP in this setting, this correlation is still imperfect. CRP
and faecal calprotectin may thus be best used as ﬁrst-line tools
to decide whether or not there is a need for endoscopic or
cross-sectional imaging reassessment. In this perspective, an
interesting meta-study was recently performed, analysing the
data of six studies that included more than 550 patients and
provided blood CRP and faecal calprotectin levels together with
endoscopic scores of severity.57 In patients with symptoms
(CDAI >220), the sensitivity of CRP ≤5 mg/l or calprotectin
≤200 μg/g to anticipate a CDEIS ≤6 was 83% and the speciﬁcity
71%. The PPV ranged from 66% to 81% and NPV from 86%
to 73% for a prevalence of CDEIS ≤6 between 40% and 60%.
It thus means that, out of 100 patients with clinically active
disease, if endoscopy was only performed when one of the
markers was below the threshold, 38–50 colonoscopies could be
avoided. Those with both markers above the threshold would
be considered to have active lesions. However, 7–10 of them
would have a CDEIS <6 and may thus be overtreated.
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Conﬁrming response to treatment
A decrease in CRP has been clearly demonstrated in patients
clinically responding to medical treatment. The same has been
shown for faecal calprotectin.58 More recently, it was shown
that a persisting increase in CRP under anti-TNF therapy was
associated with future loss of response to the drug.59 This
suggests that biomarkers such as CRP and faecal calprotectin
could be used to conﬁrm the response to therapy and that an
adequate response should be accompanied by normalisation
of CRP and a dramatic decrease in faecal calprotectin.
Normalisation of calprotectin (<50 μg/g) is certainly more difﬁ-
cult to achieve than normalisation of CRP, and may not be con-
sidered as a therapeutic target. Nevertheless, it may represent a
state of deeper remission, probably associated with more pro-
found mucosal healing.21
Biomarkers to conﬁrm tissue healing and predict
disease relapse
Correlation coefﬁcients between faecal calprotectin and endo-
scopic scores of disease activity ranged from 0.42 to 0.73, and
the sensitivity and speciﬁcity to predict absence of mucosal
healing were 70–100% and 44–100%, respectively, depending
on the calprotectin concentration threshold used.56 60–62 In the
largest study so far, a faecal calprotectin concentration >250 μg/
g predicted large ulcers with a sensitivity of 60% and a speciﬁ-
city of 80%, and a concentration <250 μg/g predicted mucosal
healing (CDEIS <3) with a sensitivity of 94% and speciﬁcity of
62%.63 The weaknesses of faecal calprotectin as a biomarker
may be a weaker correlation with endoscopic activity in the
small bowel,60 the imperfect reﬂection of the transmural inﬂam-
matory process, and ﬁnally the unpleasant requirement for the
patient to bring a stool sample to the laboratory. While no other
marker has been speciﬁcally studied for the assessment of small-
bowel mucosal inﬂammation, the transmural process may be
better reﬂected by CRP. Indeed, in a retrospective study asses-
sing correlation between CRP concentration and various semio-
logical features at CT cross-sectional imaging, CRP correlated
more closely with transmural and mesenteric signs of inﬂamma-
tion than with purely mucosal signs of inﬂammation.64 In some
studies, the correlation between serum inﬂammatory markers,
including CRP, and endoscopic activity of the disease was close
to that of faecal calprotectin, with a correlation coefﬁcient of
∼0.70.65 For the assessment of mucosal healing, a recent suba-
nalysis of the STORI cohort suggested that the combination of
faecal calprotectin (at a threshold of 250 μg/g) and CRP (at a
threshold of 5 mg/l) may improve the ability to predict such
healing by signiﬁcantly increasing speciﬁcity above 70% while
sensitivity remained reasonably good, also above 70%.66 As for
the prediction of endoscopically active disease, the prediction of
mucosal healing with biomarkers is imperfect, with an inaccur-
acy of 30–40%. It is thus again as ﬁrst-line tests and in combin-
ation with endoscopy and/or cross-sectional imaging that these
biomarkers may be best used. The previously mentioned
meta-study also addressed this question.57 When patients with
inactive disease (CDAI ≤150) are considered, the sensitivity of
the association of CRP ≤10 mg/l and calprotectin ≤200 μg/g to
predict a CDEIS ≤3 was 78% and the speciﬁcity 58%. The PPV
ranged from 65% to 88% and NPV from 73% to 40% for a
prevalence of CDEIS ≤3 between 50% and 80%. This means
that, out of 100 patients in clinical remission, if endoscopy was
only performed when both markers were below the thresholds,
30–40 colonoscopies could be avoided. Patients with CRP or
calprotectin greater than the threshold would be considered to
have active lesions. Of these 60–70 patients, only 11–18 would
have a CDEIS ≤3 and would thus risk overtreatment.
CRP and faecal calprotectin are also predictors of CD relapse.
Globally, the sensitivity and speciﬁcity of faecal calprotectin to
predict CD clinical relapse was 43–90% and 43–88%, respect-
ively, again depending on the threshold used.67–69 In various
studies, CRP was, overall, a less powerful predictor, although
increased CRP was associated with a signiﬁcant increase in
relapse risk, the relative risk ranging between 3 and 58.70–72
The frequency with which these biomarkers should be measured
in the follow-up of patients who have achieved clinical remis-
sion is not well established. Most studies measured these
markers only once and then assessed the time to relapse or the
relapse rate over 1 year. However, preliminary data from the
GETAID STORI cohort indicate that both CRP and faecal cal-
protectin start to increase 4–6 months before the relapse, and
thus measurement of these markers every 3–4 months should be
able to catch this increase and enable the clinician to adapt the
therapeutic strategy.73
As emphasised above, in patients with longstanding stable
steroid-free remission, treatment de-escalation may be contem-
plated to try to optimise beneﬁt/risk and beneﬁt/cost ratio. The
data from the STORI cohort indicate that biomarkers, particularly
CRP and faecal calprotectin, may be complementary to endo-
scopic assessment in predicting the risk of relapse upon inﬂiximab
withdrawal.21 Increased CRP has already been associated with
increased risk of relapse after azathioprine withdrawal.74
Biomarkers have been little studied in the postoperative
setting to try to predict disease recurrence. Preliminary data
indicate that CRP is probably not sensitive enough to be useful
in this clinical setting.75 A postoperative follow-up study clearly
showed the absence of correlation between endoscopic recur-
rence and CRP. Inﬂammation at this stage may be conﬁned to
the mucosa in many cases and badly translate into systemic
inﬂammation. Faecal calprotectin seems to be much more prom-
ising. A surgical series showed normalisation of faecal calprotec-
tin in all patients after uncomplicated curative surgery within
2 month of the resection.76 This marker remained low in
patients without relapse, while it increased signiﬁcantly in
patients experiencing clinical relapse. However, the precise
timing of this increase was not speciﬁcally assessed in this study
and thus the predictive ability of faecal calprotectin in that
setting cannot be determined.
CONCLUSION
Endoscopic techniques, cross-sectional imaging and biomarkers
represent a range of potential monitoring tools for CD. They all
have theoretical advantages and drawbacks in helping clinicians
to optimise treatment strategies. However, none of these tools
has really been prospectively validated in a study aimed at
improving CD outcome. Therefore their use in the monitoring
of patients with CD in routine practice remains empirical. A
proposed algorithm of CD monitoring based on the limited
available evidence and our experience is shown in ﬁgure 4. The
standard of care in CD is still to manage patients according to
disease evolution based on clinical symptoms. However, on a
case by case basis, monitoring can be used to optimise thera-
peutic strategy, aiming at decreasing cumulative tissue damage
and its consequences. This could be particularly adapted in
situations where there is concern about disease progression,
because of disease location and extent, or history of the patients.
In this case, the use of endoscopy, cross-sectional imaging and
biomarkers should be proposed, aiming to answer speciﬁc ques-
tions leading to treatment adaptation. Biomarkers such as blood
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CRP and faecal calprotectin concentration often represent
informative ﬁrst-line tests to try to predict disease activity, tissue
healing or the risk of relapse. By choosing the thresholds of
these markers appropriately to optimise sensitivity or speciﬁcity,
up to half of endoscopic or cross-sectional imaging procedures
could be avoided. New biomarkers still in development, as well
as blood drug levels, including trough levels of biological
agents, may also improve the efﬁcacy of monitoring in the
future. Prospective studies to conﬁrm the effect of monitoring-
based therapeutic changes on key outcomes of CD are urgently
required.
Summary Box 1
▸ Monitoring of Crohn’s disease with endoscopy,
cross-sectional imaging and biomarkers aims to achieve
tighter disease control to try to prevent tissue damage, with
an optimal beneﬁt/risk and beneﬁt/cost ratio.
▸ Mucosal healing assessed by ileocolonoscopy is associated
with improved disease outcome including fewer relapses,
hospitalisations and operations.
▸ The degree of mucosal healing required to improve outcome
is not completely established.
▸ Cross-sectional imaging provides information on the small
bowel and the transmural and extramural features of the
inﬂammatory process.
▸ MRI score of activity correlates well with endoscopic score of
activity.
▸ Faecal calprotectin and blood C-reactive protein, can predict
mucosal healing and relapse of the disease with an accuracy
of 60–70%.
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